Rui Avelar - 16 Mar 2026 Form 4 Insider Report for Evolus, Inc. (EOLS)

Reporting relationship: Chief Medical Officer and Head of Research & Development
Issuer ticker: EOLS
Reported as of: 16 Mar 2026
Net transaction value: -$146,629
SEC form: 4
Accepted by SEC: 18 Mar 2026, 20:00:32 UTC
Prior SEC filing: 19 Feb 2026
Next SEC filing: 20 Mar 2026
Source filing: View source filing
Reporting owner signature: /s/ Jeffrey J. Plumer, as attorney-in-fact for Rui Avelar

Key filing fact

Rui Avelar filed Form 4 for Evolus, Inc. (EOLS) on 18 Mar 2026.

Key facts

This page summarizes Rui Avelar's Form 4 filing for Evolus, Inc. (EOLS).
3 reported transactions and 1 derivative row are listed below.
Accepted by SEC: 18 Mar 2026, 20:00.

Change

Previous filing in this sequence was filed on 19 Feb 2026.
Current net transaction value: -$146,629.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001432063 Primary reporting owner

Avelar Rui

Relationship: Chief Medical Officer and Head of Research & Development
Address: 520 NEWPORT CENTER DR., SUITE 1200, NEWPORT BEACH
Signature: /s/ Jeffrey J. Plumer, as attorney-in-fact for Rui Avelar
Signature date: 18 Mar 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

EOLS transaction

Common Stock

Options Exercise

Transaction value
Shares: +8,804
Change %: +1.9%
Price: $0.000000^*
Shares after: 460,538
Date: 16 Mar 2026
Ownership: Direct
Footnotes: F1

EOLS transaction

Common Stock

Sale

Transaction value: $146,629
Shares: -29,996
Change %: -6.5%
Price: $4.89
Shares after: 430,542
Date: 17 Mar 2026
Ownership: Direct
Footnotes: F2, F3

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

EOLS transaction Derivative

Performance Restricted Stock Units

Options Exercise

Transaction value
Shares: -8,804
Change %: -50%
Price: $0.000000^*
Shares after: 8,802
Date: 16 Mar 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 8,804
Exercise price
Footnotes: F1

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Rule 10b5-1 trading plan

These transactions were reported as open-market trades under a Rule 10b5-1 plan. The plan lets an insider set trading instructions in advance, which can reduce the risk of trading while in possession of material nonpublic information.

Original filing language: transaction made pursuant to a contract, instruction, or written plan intended to satisfy Rule 10b5-1(c).

Explanation of responses 3 footnotes

Footnote F1

As previously reported, on February 7, 2024, the Reporting Person was granted 17,606 performance restricted stock units ("PSUs") at target pursuant to the Evolus, Inc. 2017 Omnibus Incentive Plan. The PSUs were subject to performance conditions based on certain pre-specified revenue and defined non-GAAP operating profit measured over the Issuer's 2024 and 2025 fiscal years. The Compensation Committee certified achievement at 100% of target, resulting in 17,606 earned PSUs. Of the earned PSUs, 50% vested and settled on March 16, 2026, resulting in the issuance of 8,804 shares of the Issuer's common stock. The remaining 8,802 PSUs remain outstanding and are scheduled to vest on February 7, 2027, subject to continued service. The number of shares reported reflects rounding adjustments applied in accordance with the terms of the award and administrative procedures.

Footnote F2

The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person and represent shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of multiple PSU and restricted stock unit awards.

Footnote F3

The shares were sold in multiple trades at prices ranging from $4.8874 to $4.945. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.

SEC remarks

Chief Medical Officer and Head of Research & Development